These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 39080317)

  • 1. Synergistic antibacterial activity of ceftazidime-avibactam in combination with colistin, gentamicin, amikacin, and fosfomycin against carbapenem-resistant Klebsiella pneumoniae.
    Tüzemen NÜ; Önal U; Merdan O; Akca B; Ener B; Özakın C; Akalın H
    Sci Rep; 2024 Jul; 14(1):17567. PubMed ID: 39080317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of ceftazidime-avibactam combined with different antimicrobials against carbapenem-resistant
    Wu Y; Yu W; Chu X; Zhang J; Jia P; Liu X; Zhu Y; Xu Y; Yang Q
    Microbiol Spectr; 2024 Jun; 12(6):e0010724. PubMed ID: 38712934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the Synergy of Ceftazidime-Avibactam in Combination with Meropenem, Amikacin, Aztreonam, Colistin, or Fosfomycin against Well-Characterized Multidrug-Resistant Klebsiella pneumoniae and Pseudomonas aeruginosa.
    Mikhail S; Singh NB; Kebriaei R; Rice SA; Stamper KC; Castanheira M; Rybak MJ
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31182535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of In Vitro Efficacy of Ceftazidime-Avibactam, Meropenem, and Colistin Single and Binary Combinations Against Carbapenem Resistant Klebsiella pneumoniae Strains Isolated from Various Clinical Specimens].
    Köle M; Sesli Çetin E; Şirin MC; Cicioğlu Arıdoğan B
    Mikrobiyol Bul; 2022 Apr; 56(2):230-250. PubMed ID: 35477227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Potential Use of Ceftazidime-Avibactam Against Carbapenem Resistant
    Nasomsong W; Nulsopapon P; Changpradub D; Pongchaidecha M; Pungcharoenkijkul S; Juntanawiwat P; Simsiriporn W; Santimaleeworagun W
    Drug Des Devel Ther; 2021; 15():3095-3104. PubMed ID: 34295150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
    Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
    Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro synergistic activity of fosfomycin in combination with meropenem, amikacin and colistin against OXA-48 and/or NDM-producing
    Erturk Sengel B; Altinkanat Gelmez G; Soyletir G; Korten V
    J Chemother; 2020 Sep; 32(5):237-243. PubMed ID: 32228228
    [No Abstract]   [Full Text] [Related]  

  • 8. In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects.
    Bianco G; Boattini M; Comini S; Iannaccone M; Bondi A; Cavallo R; Costa C
    Eur J Clin Microbiol Infect Dis; 2022 Jan; 41(1):63-70. PubMed ID: 34462816
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Chen T; Xu W; Yu K; Zeng W; Xu C; Cao J; Zhou T
    Microb Drug Resist; 2021 Mar; 27(3):401-409. PubMed ID: 32721272
    [No Abstract]   [Full Text] [Related]  

  • 10. Evaluation of ceftazidime/avibactam alone and in combination with amikacin, colistin and tigecycline against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae by in vitro time-kill experiment.
    Wang F; Zhou Q; Yang X; Bai Y; Cui J
    PLoS One; 2021; 16(10):e0258426. PubMed ID: 34648556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of ceftazidime-avibactam in various combinations for the treatment of experimental osteomyelitis due to Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae.
    Davido B; Crémieux AC; Vaugier I; Gatin L; Noussair L; Massias L; Laurent F; Saleh-Mghir A
    Int J Antimicrob Agents; 2023 Jan; 61(1):106702. PubMed ID: 36476965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emergence of ceftazidime-avibactam resistance in bla
    Zhou J; Yan G; Tang C; Liu J; Fu P; Ding L; Yang W; Guo Y; Wang C; Lu G; Hu F
    Int J Antimicrob Agents; 2024 Jun; 63(6):107163. PubMed ID: 38570018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates.
    Montero MM; Domene Ochoa S; López-Causapé C; Luque S; Sorlí L; Campillo N; López Montesinos I; Padilla E; Prim N; Angulo-Brunet A; Grau S; Oliver A; Horcajada JP
    Microbiol Spectr; 2021 Sep; 9(1):e0058521. PubMed ID: 34319141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of Ceftazidime-Avibactam Alone and in Combination with Ertapenem, Fosfomycin, and Tigecycline Against Carbapenemase-Producing
    Ojdana D; Gutowska A; Sacha P; Majewski P; Wieczorek P; Tryniszewska E
    Microb Drug Resist; 2019 Nov; 25(9):1357-1364. PubMed ID: 31295055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversion of KPC-114 to KPC-2 in ceftazidime-avibactam- resistant/meropenem-susceptible
    Pariona JGM; Vásquez-Ponce F; Becerra J; Martins-Gonçalves T; Pariona EMM; Madueño FT; Esposito F; V de Lima A; Mello Sampaio JL; Galhardo RS; Lincopan N
    Microbiol Spectr; 2024 Oct; 12(10):e0117324. PubMed ID: 39190636
    [No Abstract]   [Full Text] [Related]  

  • 16. Activity of Ceftazidime-Avibactam Against Clinical Isolates of Klebsiella pneumoniae, Including KPC-Carrying Isolates, Endemic to New York City.
    Manning N; Balabanian G; Rose M; Landman D; Quale J
    Microb Drug Resist; 2018; 24(1):35-39. PubMed ID: 28590820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the synergistic effect of eravacycline and tigecycline against carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae.
    Huang YS; Yang JL; Wang JT; Sheng WH; Yang CJ; Chuang YC; Chang SC
    J Infect Public Health; 2024 May; 17(5):929-937. PubMed ID: 38599013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Mechanisms Driving the
    Li X; Ke H; Wu W; Tu Y; Zhou H; Yu Y
    mSphere; 2021 Dec; 6(6):e0085921. PubMed ID: 34935448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Will ceftazidime/avibactam plus aztreonam be effective for NDM and OXA-48-Like producing organisms: Lessons learnt from
    Pragasam AK; Veeraraghavan B; Shankar BA; Bakthavatchalam YD; Mathuram A; George B; Chacko B; Korula P; Anandan S
    Indian J Med Microbiol; 2019; 37(1):34-41. PubMed ID: 31424008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic effects of ceftazidime/avibactam combined with meropenem in a murine model of infection with KPC-producing Klebsiella pneumoniae.
    Zheng M; Li FH; Liu J; Li WJ; Yin RX; Cai DT; Andrey DO; Zheng SL; Gales AC; Zhang WJ; Sun J; Liao XP; Yu Y
    J Antimicrob Chemother; 2024 May; 79(5):1069-1080. PubMed ID: 38526879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.